Creative Medical Technology Holdings Inc (CELZ)

[monte379]

Hey 7figdream. Here is my take and answers. Yes, myself and other investors have sent emails to the company and have gotten a standard reply that they cannot and will not discuss anything that is not in a public release. So yes, they reply, but no, they cannot answer our questions.

There are many reason why we are sitting at this low PPS IMO. If you bought 8 months ago you know we have hovered above and below a penny most if that time. Most recently we had 7 trading days in a row where we were hammered by the toxic note from May 2018 that had to clear by May 2019. That took us well subpenny.

After that note cleared we trading up a bit on anticipation of a good Q1 report. Even though the report had many things good in it, the bottom line was that the revs generated by the 2019 doctors did not show up in the Q1. That hit to the stock caused many to leave and sell off, simple as that. Many others are watching and waiting for the right time to buy back in. A new doctor was trained yesterday and many others will be trained in June.

Then there are all these positives if you can wait for them to develop....... it’s a marathon, not a sprint.

The FDA does not regulate medical procedures performed by qualified and licensed doctors. CaverStem® has the only clinically proven procedure to treat Erectile Dysfunction with adult stem cells in the US. CaverStem® ONLY uses your own adult stem cells (not Embryonic stem cells) and they are not altered, manipulated or stored. Therefore, FDA does not object to these procedures.

CaverStem® has been shown to be effective even in patients who do not respond to PDE5 inhibitors, and, unlike PED5 inhibitors, CaverStem® and FemCelz is completely safe.

Several doctors in the US have been vetted and signed and are now OPEN and treating patients (Doctors Gershman, Said, Bieri, Liu, Narayan, Niemczyk and Sanderson). Currently you can make an appointment any of those locations along with Dr. Antonini in Rome, Italy.

Two shareholders are among the treated patients and can confirm the ease of the treatment for the patient. Testimonials have been published showing patients have been treated. Follow up testimonials will be published when ready.

CELZ added physicians California, Ohio, Texas and Tennessee (to be named soon) and CELZ will continually add the new physicians to the CaverStem® website as they come aboard. CELZ has been adding approximately 5 doctors per month in the most recent two months.

To speed up new physician training due to the demand, CELZ added additional medical personnel to travel to each physicians office/area to train.

Due to the increased international demand and to compliment the existing relationship with Scott Shea, Thomas Bianchi has joined the company as the international sales representative. DD will tell you that interest in increasing in Europe.

Marketing Director David Brandt has been interviewing patients and is preparing customer testimonial videos. The first ones were posted this week.

CELZ has started treating the first patients with the FemCelz procedure for the treatment of female sexual dysfunction using stem cells from the patient's own bone marrow. Many of the existing CaverStem® affiliated physician's will also treat female patients for sexual function and we anticipate that they will be the leaders in progressing the FemCelz program.

Over 50 domain names have been registered showing that more doctors are being vetted or have shown interest. These includes MANY cities and states in the USA, and now we KNOW there are domains registered in Russia (PromoMed, Dr. Pushkar), Germany, France, Switzerland (Alto Uro, Dr. Bachmann) and Austria.

CELZ has begun a series of mailer and email campaigns introducing the CaverStem® procedure to licensed physicians in the areas of urology, OB/GYN, sexual function and plastic surgery. This campaign which will be expanded on a monthly basis with follow up mailers and emails and calls from our sales representatives. It's the goal to reach out to a minimum of 2500 new physicians each month by these methods. CELZ reported good replies from the emails.

CELZ has also increased its online presence on Social Media and by placing banner advertising on websites and search engines attracting the active male. They are currently scripting television commercials which will be edited to direct patients to each physician in their area.

U.S. and international agreements have been reached for exclusive distribution rights for the FDA approved Generation 2 bone marrow harvest technology which has been used with multiple ED patients with excellent results, however Government exemptions are required for the ongoing import of the device in Russia. This is a slow and tedious process in getting approval, therefore CELZ progress has been delayed in Russia.

Your DD will show that Dr. Gershman has been performing the procedure with EXCELLENT results…Up to 90% success rate, even in difficult patients. CELZ has received positive feedback from treating physicians of a 70% to 90% efficacy in their patients. Obviously results differ depending on the age and health of the patient and cause and severity of their erectile dysfunction.

A one-year trial has concluded and will PROVE the same results. You can watch for results here; https://clinicaltrials.gov/ct2/show/NCT03699943?recrs=deghi&fund=2&lupd_s=09%2F27%2F2018&lupd_d=14

CELZ is working on their paper for publication. The Principal Investigator is Dr. Jacob Rajfer, MD University of California, Los Angeles... top notch credentials. This is ongoing and in compliance with contractual obligations. Once the paper has been approved by The Journal of Translational Medicine and a publication date advised, shareholders will be updated. Additionally, CELZ has designed an electronic patient registry that is intended to include data from the clinical trial, data from treating physicians using centrifuge technology with a 30cc to 60cc bone marrow aspiration and the second generation, needle only.

Revenue has now started, CELZ is cash flowing. Additional physicians are scheduled for training, patients are being treated and revenues are being generated and increasing each month. Evidence of this are the scores of patients treated in Rome and NM. From these revenue streams, CELZ anticipates reaching financial self-sufficiency by revenues from sales in 2019.

CELZ has Institutional Investors now, slowing dilution and providing much better terms as CELZ completes the commercialization phase. Two of the most recent notes that were issued in 2018 were renegotiated providing cash for operations.

CELZ signed with PatientGain to redesigning the website for the anticipated HUGE volume of traffic CaverStem® and FemCelz will generate. This has generated many calls to the vetted doctors.

CELZ anticipates acquiring the Virility Centers of America brand from affiliate company Creative Medical Health, Inc. The use of the Virility Centers brand is related to male and female wellness clinics, including sexual function (CaverStem® and FemCelzTM), incontinence and infertility. This brand will compliment the CaverStem® and FemCelz brands.

CaverStem® and FemCelz are just TWO of SEVERAL patents held by CMTH.
4 NEW patents were applied for in 2018.

CELZ anticipates commercialization of StemSpine in late 2019 or early 2020 bringing online a third revenue source.

Management has already successfully commercialized Medistem providing a large return on investment for the shareholders.

CaverStem®, FemCelz, StemSpine & AmnioStem have all be TRADEMARKED
CaverStem is now a REGISTERED TRADEMARK. Caverstem®